NCT02405078View on ClinicalTrials.gov

Tumor-Specific Clonotype, Metabolic Profile, and PET/CT in Predicting Chemotherapy Response in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

October 13, 2015

Primary Completion Date

October 3, 2022

Study Completion Date

October 3, 2022

Conditions
Recurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma
Interventions
DRUG

Chemotherapy

Given standard salvage chemotherapy

PROCEDURE

Computed Tomography

Undergo FDG-PET/CT scan

DRUG

Fludeoxyglucose F-18

Undergo FDG-PET/CT scan

PROCEDURE

Positron Emission Tomography

Undergo FDG-PET/CT scan

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT02405078 - Tumor-Specific Clonotype, Metabolic Profile, and PET/CT in Predicting Chemotherapy Response in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma | Biotech Hunter | Biotech Hunter